Skip to content

Explore Grants

Recipient Purpose Term Source Amount
Bipartisan Policy Center, Inc. To analyze policy options related to reference pricing and patent and market exclusivity. 2019 - 2020 LJAF $197,208
Brigham & Women's Hospital, Inc. To support the Promoting a Competitive Market for High-Cost Biologic Drugs project. 2019 - 2021 LJAF $470,386
Brigham & Womens Hospital, Inc. To support the Program On Regulation, Therapeutics, and Law (PORTAL), which will evaluate the impact of drug innovation incentive policies. 2016 - 2017 LJAF $742,905
Brigham & Womens Hospital, Inc. To support the Program On Regulation, Therapeutics, And Law (PORTAL) Biomarker Research Consortium. 2016 - 2020 LJAF $2,024,093
Brigham & Womens Hospital, Inc. To evaluate the impact of Pharmacy Benefits Managers on prescription drug pricing. 2017 - 2018 LJAF $77,315
Brigham & Womens Hospital, Inc. To support the Program On Regulation, Therapeutics, And Law (PORTAL). 2017 - 2020 LJAF $3,268,850
Center for Health Policy Development To support a working group of state health policy experts and stakeholders to examine emerging strategies for addressing the high cost of prescription drugs. 2016 - 2017 LJAF $146,271
Center for Health Policy Development To support the launch of the Center for Prescription Drug Price Action. 2017 - 2019 LJAF $2,021,350
Civica, Inc. To promote availability and affordability of essential generic drugs. 2018 - 2023 LJAF $1,000,000
Civica, Inc.** To promote availability and affordability of essential generic drugs. 2018 - 2030 LJAF $9,000,000
Doctors for America To develop a physician-centered coalition that will educate the public and key stakeholders about prescription drug pricing in the United States. 2019 - 2021 LJAF $552,596
Evidence for Healthcare Improvement To produce Institute for Clinical and Economic Review reports on new drugs' comparative effectiveness, cost effectiveness, and potential budget impact. 2015 - 2017 LJAF $5,232,002
Evidence for Healthcare Improvement To support independent analyses by the Institute for Clinical and Economic Review on the comparative cost effectiveness for newly-introduced pharmaceutical drugs. 2017 - 2021 LJAF $13,966,892
Families USA Foundation, Inc. To provide Grantee with general operating support. 2019 - 2021 LJAF $1,400,000
George Mason University Foundation, Inc. To develop and disseminate policy options related to the negotiation of prescription drug prices by Medicare. 2018 LJAF $37,475
Health Care For All Inc. To educate the public, policymakers, and key stakeholders about drug price increases and increased drug pricing transparency, and strengthen efforts to counter marketing efforts by the pharmaceutical industry. 2019 - 2020 LJAF $374,648
HealthPartners Institute To analyze the characteristics and consequences of off patent, non-competitive drugs, and assist policymakers in developing policy proposals to address price spikes common among these types of drugs. 2019 - 2021 LJAF $210,297
Henry J. Kaiser Family Foundation To examine trends in prescription drug prices and Medicare Part D formulary coverage and broadly disseminate the findings through policy briefs, papers, and convenings . 2018 - 2020 LJAF $484,587
Henry J. Kaiser Family Foundation To provide researchers, policymakers, and the public with accessible, unbiased information about the Medicaid pharmacy benefit and policy options to lower Medicaid drug spending. 2019 - 2020 LJAF $423,447
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2016 - 2018 LJAF $1,060,500
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2017 - 2018 LJAF $200,000
Initiative for Medicines, Access, & Knowledge, Inc. To produce a report that will outline strategies to address pharmaceutical patents and pricing structures. 2016 LJAF $209,500
Initiative for Medicines, Access, & Knowledge, Inc. To support efforts to provide patients with affordable access to life-saving medications and improve public health. 2017 - 2019 LJAF $3,958,828
Johns Hopkins University To promote the adoption of a waste-free prescription drug formulary by private corporations in place of the current drug rebate system. 2018 - 2021 LJAF $940,607
Arnold A decorative icon